Diagnosis and treatment progress of primary central nervous system lymphoma
10.3760/cma.j.cn115356-20230110-00012
- VernacularTitle:原发中枢神经系统淋巴瘤诊治进展
- Author:
Wenrong HUANG
1
Author Information
1. 解放军总医院第五医学中心血液病医学部 淋巴瘤-浆细胞疾病科，北京 100071
- Keywords:
Lymphoma;
Central nervous system neoplasms;
High-throughput nucleotide sequencing;
Molecular targeted therapy;
Chimeric antigen receptor T-cells;
Hematopoi
- From:
Journal of Leukemia & Lymphoma
2023;32(3):138-142
- CountryChina
- Language:Chinese
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is a rare lymphoma type. The prognosis of PCNSL patients after treated by traditional therapy regimen is very poor. The way to evaluate the prognosis of PCNSL and to increase therapeutic efficacy have become the clinical problem. The 64th American Society of Hematology (ASH) annual meeting reported the latest research progress of diagnosis and treatment of PCNSL, including image examination, genetic sequencing, targeted therapy, chimeric antigen receptor T-cell (CAR-T) therapy and autologous hematopoietic stem cell transplantation (ASCT). This paper reviews the latest progress of PCNSL in the 64th ASH annual meeting.
